TPP allies with Sprint Bioscience to develop cancer drugs

11/1/2012 | Pharmaceutical Business Review Online

Sprint Bioscience and TPP Global Development agreed to collaborate in the development of small molecule choline kinase inhibitors for treatment of cancer. "Choline kinase is an exciting metabolic target and fits well within the rest of TPP's cancer metabolism portfolio," TPP CEO Tom Brown said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Information Technology
HealthPartners
MN
Senior Counsel – Healthcare Regulatory #29099BR
Amgen
Thousand Oaks, CA
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
R&D Engineer
Access Scientific
San Diego, CA, CA
Project Manager RA (US/UA/00/0105/SL) - 1400000A7F
Abbott
San Jose, CA